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ACLT changes the biomechanical properties of articular cartilage more
than cartilage thickness although it seems that three months after ACLT,
cartilage thickness is less than control group. On the other hand, in
both femur and tibia cartilage seems to become thicker following LPLT;
however, none of these changes is statictically signiﬁcant.
Apparently, destructive effects of ACLT are more pronounced on tibial
cartilage. 12 weeks after ACLT, tibial cartilage strength and young
modulus decreased signiﬁcantly, although 10 seassions of LPT reversed
this process completely. Same trend was observed in femural cartilage
but these changes were not statistically signiﬁcant.
Conclusions: Following ACLT articular cartilage softens and its strength
decreases. It seems that therapeutic laser can help cartilage to resume
its original characteristics.
Table 1.
Fig. 1.
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MODULATING MAPK SIGNALING CAN ATTENUATE THE SEVERITY
OF OSTEOARTHRITIS
Y. Xiao, I. Prasadam, R. Crawford. Queensland Univ. of Technology,
Brisbane, Australia
Purpose: Osteoarthritis (OA) is the most common musculoskeletal
disorder and represents a major health burden to society. OA is associated
with the irreversible degeneration of articular cartilage. Notably, in
this condition, articular cartilage chondrocytes undergo phenotypic and
gene expression changes that are reminiscent of their hypertrophic
differentiation in the growth plate during skeletal development. Also, the
adjacent subchondral bone shows signs of abnormal mineral density and
enhanced production of bone turnover markers, indicative of osteoblast
dysfunction. Our previous study ﬁndings suggest that Extracellular
signal-regulated kinases (ERK) signaling is activated in both in OA
subchondral bone and cartilage. The present study is a follow up of
our previous ﬁndings to identify whether the pharmacological inhibition
ERK signaling pathway slows down the progression of OA.
Methods: We developed three different types of OA rat models:
Menisectomy (MSX) induced OA, Anterior cruciate ligament transaction
(ACLT) induced OA and Mono-ido-acetate (MIA) induced OA to test
whether U0126, a MAPK-ERK1/2 pathway inhibitor shows any protective
effects towards OA cartilage degeneration and subchondral bone changes.
The cause of disease occurrence is different in the above models;
therefore the obtained data will show how the drug is acting in different
types of OA conditions. From day 7 post-surgery treatment groups were
given an intra-articular injection of ERK1/2 inhibitor (UO126) every
2 days at a concentration of 0.5 mM in 50ml using 30G needle for
8 weeks. The control group received same volume of vehicle alone
(saline+ DMSO) without administration drug. At the end of each time
point rats were euthanized and knee joints were parafﬁn embedded.
Serial 5mm sections obtained at 100mm intervals from the non weight
bearing region and weight-bearing region of each knee joint were
stained with safranin O-fast green, Type 10 collagen (COL10), runt-related
transcription factor-2 (RUNX2) and a disintegrin and metalloproteinase
with thrombospondin type 1 motif-5 (ADAMTS5). OA severity in the
tibial plateau was evaluated according to Mankin’s histologic grading
system (Mankin’s score: 0 to 14), and a cartilage destruction score
was assigned for each knee sample (n =10). Micro-Ct was performed
to see the protective effects of U0126 on subchondral bone. Cartilage
and subchondral bone tissue lysate was extracted from drug treated vs.
untreated animals and western blotting technique was applied to see
the molecular differences.
Results: pERK-1/2 was signiﬁcantly increased in the cartilage and
subchondral bone of all three OA models compared to sham conﬁrming
the pathological relevance of this signaling pathway in OA. U0126 down
regulated the pERK-1/2 expression in treatment group conﬁrming the
efﬁcacy of U0126 in inhibiting ERK at in vivo level. Furthermore, U0126
treated animal models showed signiﬁcantly reduced Mankin score (up
to 40–50%), less proteoglycan depletion, decreased expression of COL0,
RUNX2 and ADAMTS5 proteins in all three OA models compared to
untreated controls (Figure 1). OA knees showed increase in BV and BV/TV
compared to shams at week 8. The increased BV and BV/TV were partially
reversed when the animals were treated with the U0126, indicating the
therapeutic beneﬁts of U0126 on OA subchondral bone changes.
Conclusions: Together, these ﬁndings raise the possibility that ERK
blockade can be used as a therapeutic approach to inhibit OA articular
cartilage degeneration and subchondral bone changes.
Fig. 1.
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Objective: Efﬁcacy, safety and tolerability evaluation of a single oral dose,
1200mg sachet of chondroitin 4&6 sulfate (Chondrosulf® 1200) versus
placebo (superiority study) and versus 3 daily capsules of chondroitin
4&6 sulfate 400mg (Chondrosulf®400), during 91 days, in patients with
knee OA (non inferiority study).
Methods: Comparative, double-blind, randomized, multicenter study, in
parallel groups, including 353 patients of both genders, over 45 years,
with knee OA for at least 6 months. Minimum inclusion criteria was a
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Lequesne Index (LI) ≥7 and pain ≥40mm on a visual analogical scale
(VAS). LI and VAS were assessed after 30, 60 and 91 days. Global efﬁcacy
evaluation and general product tolerability was also performed.
Results: Results were conﬁrmed both in per protocol (PP) and intend to
treat (ITT) population.
Non-inferiority was demonstrated after 3 month treatment between the
oral daily single dose of CS 1200 formulation and the 3 daily capsules of
CS 400 (delta = 0.13, [−0.81;1.08]).
Patients treated with CS 1200 or CS 3*400 were signiﬁcantly improved
compared to placebo in terms of LI (p < 0.0001).
LI score of patients treated with Chondrosulf® was signiﬁcantly improved
in both groups of CS4&6 at D60 and D91 (p< 0.01 and <0.001
respectively).
Pain scores were signiﬁcantly improved in both treatment groups at D91
(p =0.0052) compared to baseline and placebo.
The global efﬁcacy evaluation by patients and investigators showed a
statistically signiﬁcant superiority of both CS 1200 and CS 400 groups
compared to placebo after 60 and 91 days.
No signiﬁcant difference in terms of tolerance and tolerability was
observed between the 3 groups.
No serious AE were reported. No AE were related to study drug.
Conclusion: This study suggests that daily administration of an oral
sachet of 1200mg of chondroitin 4&6 sulfate (Chondrosulf®) allows a
signiﬁcant clinical improvement compared to placebo. A similar clinical
improvement was observed between the oral daily single dose of CS 1200
formulation and the 3 daily capsules of CS 400. No signiﬁcant difference
in tolerance and tolerability was observed across the two chondroitin
sulphate groups as compared to placebo.
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TERIPARATIDE AS A CHONDRO-REGENERATIVE THERAPY FOR
INJURY-INDUCED KNEE OSTEOARTHRITIS
E.R. Sampson, M.J. Hilton, R.A. Mooney, H. Awad, R.N. Rosier, M.J. Zuscik.
Univ. of Rochester Med. Ctr., Rochester, NY, USA
Purpose: Currently, there are no disease-modifying therapeutic strategies
for osteoarthritis (OA), a degenerative joint disease projected to
afﬂict more than 67 million Americans by 2030. In OA, the cells
responsible for maintenance of joint cartilage, articular chondrocytes
(AC) inappropriately undergo a maturational program normally only
associated with endochondral ossiﬁcation. Therefore, signaling pathways
that govern chondrocyte maturation represent candidate therapeutic
targets. Parathyroid hormone (PTH) induces chondrocyte matrix
synthesis and suppresses maturation via the PTH receptor 1 (PTHR1),
which we found to be up-regulated in ACs following meniscal injury and
during OA in humans and in injury-induced knee OA in mice. Thus,
we hypothesized that recombinant human PTH(1–34) (teriparatide)
would inhibit aberrant chondrocyte maturation and associated articular
cartilage degeneration.
Methods: PTHR1 levels were analyzed in injured and arthritic human
and mouse cartilage samples via immunograding and qPCR. We
administered systemic teriparatide, an FDA-approved treatment for
osteoporosis (Forteo), either immediately or beginning 8 weeks after
meniscal/ligamentous injury (MLI) in mice. Knee joints were harvested
at 4, 8, or 12 weeks post-MLI to examine the effects of teriparatide
on OA bone and cartilage phenotypes using microCT, histologic scoring,
morphometric methods and immunostaining. Bone phenotypes assessed
included subchondral bone volume and osteophyte formation. Cartilage
phenotypes examined included articular cartilage integrity and area, as
well as molecular assessment of AC maturation.
Results: Human cartilage samples harvested from non-OA patients
undergoing meniscal repair surgery or end-stage OA patients undergoing
total knee arthroplasty displayed increased PTHR1 levels as assessed
by immunostaining. Similarly, mice with progressing OA induced
by MLI surgery displayed increased PTHR1 levels as determined
by immunostaining and qPCR. Micro-computed tomography revealed
increased bone volume in knee joints following MLI. Teriparatide
treatment increased bone volume in both sham-operated and MLI
joints, conﬁrming the bone anabolic effect of the systemic therapy.
However, osteophyte formation initiated by MLI surgery was not
exacerbated by teriparatide treatment and no osteophytes were evident
in sham-operated joints from teriparatide-treated mice. Furthermore,
targeted activation of the PTHR1 in ACs by systemic teriparatide
treatment was demonstrated by increased expression of Jagged-1, a
direct transcriptional target of the receptor’s downstream signaling
pathway. Immediate systemic administration of teriparatide increased
proteoglycan abundance and decelerated articular cartilage degeneration.
Strikingly, delayed teriparatide treatment beginning 8 weeks post-injury
induced a chondro-regenerative effect. Overall, these effects correlated
with up-regulation of proteoglycan-4 and decreased levels of matrix
metalloproteinase-13, type X collagen and Runx2 in ACs.
Conclusions: These preclinical ﬁndings provide proof-of-concept for the
use of teriparatide (Forteo) to decelerate cartilage degeneration in OA
patients and to delay the onset of morbidity associated with end-stage
disease.
